Pressmeddelanden, rapporter och bolagsmeddelande för Genetic Analysis

Ronny Hermansen, CEO of Genetic Analysis, reported strategic progress and international expansion in the first quarter of 2025. The company saw a decrease in sales by 27% compared to the same period in 2024, with total sales reaching NOK 2.4 million. Despite this, the gross margin improved to 84%, and cost savings led to a better EBITDA of NOK -3.5 million. The net loss was reduced to NOK -4.6 million. Significant events included the launch of the GA-map® Dysbiosis Test in China and a directed share issue raising NOK 12.8 million to support collaborations and innovation. Additionally, changes were made to the Board of Directors with Morten Jurs appointed as Chairman and Ove Öhman as a new board member.

The Board of Directors has decided to proceed with a Subsequent Offering, allowing shareholders to subscribe for one new share for every six existing shares at NOK 0.86 per share. Subscription rights will be issued to shareholders registered in Euronext VPS as of June 2, 2025, and these rights will be tradeable on the Spotlight Stock Market from June 5 to June 12. Subscriptions close on June 16, with oversubscriptions allowed. If fully subscribed, the offering will raise NOK 7.1 million, contributing approximately NOK 6.0 million to the company's capital. The offering aims to provide shareholders not included in the previous Directed Issue a chance to acquire additional shares. A document detailing the terms is expected to be published around June 2, 2025. Sedermera Corporate Finance AB is the appointed financial advisor. The board reserves the right to cancel the offering. For more information, contact CEO Ronny Hermansen via email.

Genetic Analysis, under CEO Ronny Hermansen, reported strategic progress and international expansion in Q1 2025. Operating income was NOK 4.0 million, with sales at NOK 2.4 million, a 27% decrease from the previous year due to inventory adjustments by partners. Despite lower sales, the gross margin improved to 84%, and cost-saving measures led to better EBITDA and reduced net loss compared to Q1 2024. The company launched the GA-map® Dysbiosis Test in China and announced a directed share issue of NOK 12.8 million to support collaborations, including with Ferring. Changes to the Board of Directors included appointing Morten Jurs as Chairman and Ove Öhman as a new member.

Genetic Analysis AS har genomfört en riktad nyemission av aktier med ett bruttoproveny på cirka 12,8 miljoner NOK, godkänd vid företagets årsstämma den 19 maj 2025. Följande personer med ledande befattningar och deras närstående har tilldelats aktier: - Morten Jurs, styrelseordförande, har via Jurs AS tilldelats 348,837 aktier. - Ove Öhman, styrelseledamot, har via Meja AB tilldelats 575,000 aktier. - Rune Sørum, styrelseledamot, har via Tind AS tilldelats 250,000 aktier och har även 70,000 optioner. - Thorvald Steen, styrelseledamot, har via Kagge AS tilldelats 930,250 aktier. - Ronny Hermansen, VD, har via InVitroDia AS tilldelats 350,000 aktier och har 716,667 optioner. - Christina Casén, SVP Medical & Clinical Affairs, har tilldelats 348,837 aktier och har 359,997 optioner. - Lars Tiller, Operationschef, har tilldelats 23,256 aktier och har 210,000 optioner. - Kari Furu, Chef för produkt- och affärsutveckling, har tilldelats 34,884 aktier och har 276,667 optioner. - Tore Grøttum, tf. CFO, har tilldelats 600,000 aktier. Aktierna har tilldelats till ett pris av 0,86 NOK per aktie. För mer information, kontakta Tore Grøttum via e-post: tg@genetic-analysis.com.

The general meeting approved several resolutions related to Genetic Analysis AS. The company's share capital will be increased through two directed issues, with new shares issued at NOK 0.86 each. The first increase involves NOK 6,857,707.20 for 11,429,512 shares, and the second involves NOK 2,076,638.40 for 3,461,064 shares. Existing shareholders' preferential rights are waived, and subscriptions and payments are due by May 2025. The annual accounts and directors' report for 2024 were approved, along with auditor remuneration. The board of directors was elected, with specified remuneration for members. The nomination committee was reelected, with remuneration set for its members. The board was authorized to increase the share capital up to NOK 11,400,000 and to acquire own shares. The share option program was extended with an additional 2,000,000 options, and the board was authorized to increase share capital by up to NOK 3,223,551 for this program. For detailed information, refer to the AGM notice on the company's website.

GA has announced a conditional share issue, receiving subscriptions for 14,889,576 new shares at NOK 0.86 each, potentially raising NOK 12.8 million before costs. The board has approved this and will propose it at the AGM on May 19, 2025. The subscription price matches the average trading price on the Spotlight Stock Market over the last 15 days up to April 24, 2025. The board invited certain shareholders and proposed board members to subscribe, with 23% of the issue taken by the board and management. This Directed Issue deviates from existing shareholders' preferential rights due to the need for quicker capital raising and market conditions. A Subsequent Offering is planned for shareholders not included in the Directed Issue, pending AGM approval. The Directed Issue will increase the number of shares by 30%, from 49,383,271 to 64,273,847, and the share capital by NOK 8,934,345.60. The funds will support ongoing projects and new business collaborations, particularly in microbiome diagnostics. An Innovation Norway Grant of NOK 1,125 million is also conditional on raising NOK 2.5 million from this equity offering. The company considers this issue essential for financial flexibility and future growth.

Shareholders of Genetic Analysis AS are encouraged to submit a proxy with voting instructions before the general meeting or notify the company if they wish to attend in person. The meeting agenda includes opening remarks, election of a chairperson, approval of the notice and agenda, and various resolutions regarding share capital increases, approval of annual accounts, and remuneration for auditors and board members. The board proposes a share capital increase through a directed issue, which requires deviation from existing shareholders' rights, but justifies this decision based on timing and cost considerations. A potential repair issue for smaller shareholders is also discussed. The board seeks approval for the annual accounts and proposes remuneration for the company's auditor. The election of new board members and their remuneration is outlined, along with the re-election of the nomination committee and their remuneration. The board also seeks authorization to increase share capital and acquire own shares, as well as to extend the share option program. Shareholders may appoint a proxy to vote on their behalf, and relevant documents are available on the company's website.

CEO Ronny Hermansen expressed enthusiasm for the proposal to appoint Morten Jurs as Chairman of the Board, highlighting Jurs' extensive experience in diagnostics, pharma, and mergers and acquisitions. Jurs is currently CEO of SpinChip Diagnostics and has a history of successful leadership in both public and private companies. Hermansen also welcomed Ove Öhman to the board, noting his entrepreneurial background in the life sciences and diagnostics industries. Additionally, Hermansen thanked Dr. Jethro Holter for his service as Chairman and wished him well in his new role as CEO of AdjuTec Pharma.

GA has announced a conditional share issue, receiving subscriptions for 14,889,576 new shares at NOK 0.86 each, potentially raising approximately NOK 12.8 million before costs. The board approved the subscriptions and will propose the issue at the AGM on May 19, 2025. The subscription price matches the average trading price on the Spotlight Stock Market. The board invited select shareholders and proposed board members to subscribe, with 23% of the issue taken up by the board and management. The Directed Issue deviates from shareholders' preferential rights, as a rights issue would take longer and expose the company to market fluctuations. The board deemed the Directed Issue beneficial for shareholders and plans a Subsequent Offering for those not invited to participate, contingent on AGM approval. The Directed Issue will fund collaborations, including with Ferring, and expand diagnostics in the microbiome field. The issue will increase the number of shares by 30%, and the share capital will rise from NOK 29,629,962.60 to NOK 38,564,208.20. The company faces financial risks due to limited liquidity but sees the issue as a means to enhance sales, marketing, and development projects. If additional capital isn't raised, strategic alternatives may be needed. Subscribers include BioRad Inc and various investment firms, with board and management members contributing as well. Total subscriptions amount to NOK 12,805,895.